Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Research

| More

GSK Pharmaceuticals - Weak quarter impacted by COVID-19 - ICICI Securities

Posted On: 2020-07-29 22:13:07


GlaxoSmithKline Pharmaceuticals Limited's (GSKP) Q1FY21 results were below our estimates on all fronts. Revenue declined 17.7% YoY to Rs6.5bn (I-Sec: Rs7.1bn), EBITDA margin declined 340bps YoY to 17.6% (I-Sec: 20.0%) and adjusted PAT declined 26.7% YoY to Rs791mn (I-Sec: Rs1.0bn). Weaker than expected performance was decline in top brands owing to lockdown caused by COVID-19. As GSKP's focus is on acute therapies we expect pressure in the uncertain near term to sustain. GSKP's exposure only to domestic formulations, strong balance sheet and strong brand equity augurs well for the company but current valuations seem fair, hence we maintain HOLD recommendation with a revised target price of Rs1,432/share (earlier: Rs1,453/share).

- Weak than anticipated performance: Revenue declined 17.7% during the quarter against our estimate of a 10.0% decline due to negligible sales of Zinetac (ranitidine) as well as impact from nationwide lockdown post COVID-19. Declining sales of low margin Zinetac (ranitidine) as well as lower raw material cost lifted gross margins by 370bps YoY but lower sales resulted in margin dropping 370bps QoQ. Employee cost rose 6.4% but other expenses declined 16.0% YoY to support EBITDA. As a percentage of sales employee cost and other expenses jumped 530bps and 40bps YoY respectively resulting in a contraction of 340bps in EBITDA margin. Company reported a gain of Rs427mn in the form of interest on income tax refund.

- Key products performance: As per AIOCD data the GSKP has reported decline of 15.4%. Betnovate, Betnovate N and Eltroxin have reported healthy YoY growth of 12.6%, 12.7% and 7.7% respectively for the quarter. However, Augmentin, Synflorix, Calpol, T-BACT, Ceftum and Betnesol have reported a YoY decline of 6.0%, 14.3%, 7.1%, 8.1%, 16.0% and 16.9% respectively. Infanrix Hexa continues its strong momentum with 34.9% YoY growth albeit on a smaller base. Company has stated that despite the challenging environment its market share has grown in the quarter.

- Outlook: FY21 estimates would optically appear lower due to Zinteac (ranitidine) sales in the base. However, we expect FY22 to report a strong growth both on revenue and earnings front. We expect 6.8% revenue and 11.9% PAT CAGR over FY20-FY22E driven by growth in power brands and key therapies like vaccines and VMN. Minimal capex requirement would aid cashflow generation of ~Rs13bn over the next two years.

- Valuations and risks: We reduce our revenue and earnings estimates for FY21E-FY22E by 1-2% and 1-4% to factor in the weaker than anticipated quarter performance impacted due to COVID-19. We maintain HOLD with a revised target price of Rs1,432/share based on 40xFY22E earnings (earlier: Rs1,453/share). Key downside risks: addition of key drugs in National List of Essential Medicines (NLEM), product concentration and government intervention. Key upside risks: better than expected performance in key products and new significant product launches.

Valuations

We expect GSKP to witness an earnings CAGR of 11.9% over FY20-FY22E driven by revenue CAGR of 6.8% and EBITDA margin expansion to 21.6% in FY22E from 20.4% in FY20. Return ratios (RoE and RoCE) would continue to improve with margin expansion. The stock currently trades at valuations of 50.0xFY21E and 41.4xFY22E earnings and EV/EBITDA multiple of 33.7xFY21E and 29.4xFY22E. We remain positive on the long-term outlook considering the company's strong growth powered by its key brands, healthy return profile and rich cash reserves. However, GSKP's focus is on acute therapies where we expect pressure in the uncertain near term to sustain. Current valuations seem fair, hence, we maintain HOLD with a revised target price of Rs1,432/share based on 40xFY22E earnings (earlier: Rs1,453/share).

Shares of GLAXOSMITHKLINE PHARMACEUTICALS LTD. was last trading in BSE at Rs.1489.95 as compared to the previous close of Rs. 1462.25. The total number of shares traded during the day was 1642 in over 366 trades.

The stock hit an intraday high of Rs. 1498.45 and intraday low of 1465. The net turnover during the day was Rs. 2436780.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Pidilite Industries - Q1FY21 Result Update - ICICI Securities

Dwarikesh Sugar - Q1FY21 Result Update - ICICI Securities

Divi's Laboratories - Q1FY21 First Cut - ICICI Securities

Amber Enterprises India - Q1FY21 First Cut - ICICI Securities

Mahanagar Gas - Q1FY21 First Cut - ICICI Securities

Container Corporation of India - Q1FY21 First Cut - ICICI Securities

Bata India - Q1FY21 First Cut - ICICI Securities

RBI Monetary policy - August 6, 2020 - Xanadu Realty

MPC pauses; allows one-time restructuring - Economy - ICICI Securities

RBI Monetary Policy - V Swaminathan, Joint President - Government Business & Gold Loans, Kotak Mahindra Bank

Mr. CVR Rajendaran, CEO & MD, CSB Bank on the monetary policy announcement

Mr. Satish Magar's statement on RBI announcement on Monetary Policy

Mr. R.K.Gurumurthy, Head - Treasury, Lakshmi Vilas Bank on the RBI Monetary policy

Mr. Rajnish Kumar, Chairman, SBI and Chairman, IBA on RBI Monetary Policy

Mr. Umesh Revankar, MD and CEO, Shriram Transport Finance on the RBI monetary policy

Views on RBI Policy: Ms. Bekxy Kuriakose, Head - Fixed Income, Principal Asset Management

RBI Monetary Policy - Aug 2020 - Sujata Guhathakurta, President, Debt Capital Markets-Sales, Kotak Mahindra Bank

View on RBI Monetary Policy - Aug 2020 - Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

Views on RBI Policy - Aug 2020 - Mr. Dhiraj Rellu, MD & CEO, HDFC Securities

Monetary Policy

View on RBI Monetary Policy - Suvodeep Rakshit, Vice President & Senior Economist at Kotak Institutional Equities

Views on RBI's monetary policy - Jyoti Roy, DVP - Equity Strategist, Angel Broking Ltd

Monetary Policy - Aug 2020: Views of Mr. Amar Ambani, YES SECURITIES

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research, on the RBI policy announcement - Aug 2020

Banks and NBFCs - RBI comes to the rescue again - HDFC Securities

Realty sector on RBI's decision to permit a one-time restructuring of loans

1QFY21 Results of Alkem Lab - Angel Broking

UPL - Quant Pick - August 2020 - ICICI Securities

Mahindra & Mahindra - Q1FY21 First Cut - ICICI Securities

Motilal Oswal Financial - Company Update - August 2020 - ICICI Securities

Indian Hotels - Q1FY21 Result Update - ICICI Securities

Gujarat Pipavav Port - Company Update - August 2020 - ICICI Securities

Kajaria Ceramics - Q1FY21 First Cut - ICICI Securities

1QFY21 results of HPCL - Angel Broking

Maintain REDUCE on PSP Projects - In-line performance - HDFC Securities

Tata Consumer Products - Q1FY21 Result Update - YES Securities

TV Today - Q1FY21 First Cut - ICICI Securities

Balrampur Chini - Q1FY21 First Cut - ICICI Securities

1QFY21 results of Mahindra & Mahindra - Angel Broking

DLF - Stable performance - HDFC Securities

Mindspace Business Park REIT Listing - Angel Broking

Maintain ADD on Hindustan Petroleum Corporation - High marketing margins lead the way - HDFC Securities

1QFY21 results of Gujarat State Petronet Ltd - Angel Broking

1QFY21 results of Torrent Power Ltd - Angel Broking

1QFY21 results of Lupin Ltd - Angel Broking

1QFY21 results of Vodafone Idea - Angel Broking

1QFY21 results of KEI Industries Ltd - Angel Broking

Honeywell Automation India (Q1FY21) - BUY (Target Rs36310, Upside 33%) - YES Securities

Lupin - Q1FY21 First Cut - ICICI Securities

Lemon Tree Hotels - Q1FY21 First Cut - ICICI Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019